ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Precision Targeting of Myeloid Cells via Peptide Dendrimer-Lipid Nanocarriers: A Novel Platform for Potent Cancer Immunotherapies.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CD13 identifies S100A4Biology direct · 2026Article
- Precision Targeting of Myeloid Cells via Peptide Dendrimer-Lipid Nanocarriers: A Novel Platform for Potent Cancer Immunotherapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective targeting of myeloid cells (MCs) holds therapeutic potential as an immuno-oncology approach. However, MC targeting using existing gene delivery platforms faces many barriers to clinical use, such as production scalability and off-target delivery to the liver and non-MCs. Here, a novel peptide dendrimer-lipid (PDL) nanocarrier for systemic administration, which overcomes many of these barriers, is characterized. This MC targeting nanocarrier (MCTN) is self-assembling, de-targets the liver, and selectively targets the spleen and MCs within the tumor microenvironment (TME). MCTN is validated as a cancer vaccine platform utilizing full-length antigens, generating robust immune responses with broad HLA-haplotype coverage. Finally, using a payload encoding constitutively active interferon regulatory factor 5 (IRF5), MCTN is found to suppress solid tumor growth and modulate the TME by improving CD8+ T-cell infiltration while depleting immunosuppressive cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.